MedTrace Logo

ATL001 in Patients With Metastatic or Recurrent Melanoma

NCT03997474 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-03-07

Study results available
· View outcomes & findings →

Summary

This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity of ATL001, autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with metastatic or recurrent melanoma.

Conditions

Interventions

BIOLOGICAL

ATL001

ATL001 infusion

DRUG

Checkpoint Inhibitor

Nivolumab

Sponsors & Collaborators

  • Achilles Therapeutics UK Limited

    lead INDUSTRY

Principal Investigators

  • Medical Monitor, MD · Achilles Therapeutics UK Limited

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-15
Primary Completion
2024-09-03
Completion
2024-09-03
FDA Drug
Yes

Countries

  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03997474 on ClinicalTrials.gov